vs
Esperion Therapeutics, Inc.（ESPR）与WAFD INC（WAFD）财务数据对比。点击上方公司名可切换其他公司
WAFD INC的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$191.4M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 11.8%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 5.5%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
WAFD银行总部位于美国华盛顿州西雅图市，是美国头部银行之一，业务覆盖华盛顿州、俄勒冈州、爱达荷州、内华达州、犹他州、亚利桑那州、新墨西哥州、加利福尼亚州及得克萨斯州，共设有210家实体营业网点，为多州客户提供专业金融服务。
ESPR vs WAFD — 直观对比
营收规模更大
WAFD
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出131.9%
11.8%
两年增速更快
ESPR
近两年复合增速
5.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $191.4M |
| 净利润 | — | $64.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 43.0% |
| 净利率 | — | 33.5% |
| 营收同比 | 143.7% | 11.8% |
| 净利润同比 | — | 35.8% |
| 每股收益（稀释后） | $0.32 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRWAFD
| Q4 25 | $168.4M | $191.4M | ||
| Q3 25 | $87.3M | $188.3M | ||
| Q2 25 | $82.4M | $186.3M | ||
| Q1 25 | $65.0M | $179.8M | ||
| Q4 24 | $69.1M | $171.1M | ||
| Q3 24 | $51.6M | $188.7M | ||
| Q2 24 | $73.8M | $194.4M | ||
| Q1 24 | $137.7M | $172.0M |
净利润ESPRWAFD
| Q4 25 | — | $64.2M | ||
| Q3 25 | $-31.3M | $60.6M | ||
| Q2 25 | $-12.7M | $62.0M | ||
| Q1 25 | $-40.5M | $56.3M | ||
| Q4 24 | — | $47.3M | ||
| Q3 24 | $-29.5M | $61.1M | ||
| Q2 24 | $-61.9M | $64.6M | ||
| Q1 24 | $61.0M | $15.9M |
营业利润率ESPRWAFD
| Q4 25 | 50.6% | 43.0% | ||
| Q3 25 | -11.4% | 41.2% | ||
| Q2 25 | 8.6% | 42.8% | ||
| Q1 25 | -34.0% | 40.1% | ||
| Q4 24 | -6.4% | 35.2% | ||
| Q3 24 | -31.0% | 42.8% | ||
| Q2 24 | 3.5% | 42.6% | ||
| Q1 24 | 52.5% | 12.2% |
净利率ESPRWAFD
| Q4 25 | — | 33.5% | ||
| Q3 25 | -35.9% | 32.2% | ||
| Q2 25 | -15.4% | 33.3% | ||
| Q1 25 | -62.2% | 31.3% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | -57.2% | 32.4% | ||
| Q2 24 | -83.9% | 33.2% | ||
| Q1 24 | 44.3% | 9.2% |
每股收益（稀释后）ESPRWAFD
| Q4 25 | $0.32 | $0.79 | ||
| Q3 25 | $-0.16 | $0.71 | ||
| Q2 25 | $-0.06 | $0.73 | ||
| Q1 25 | $-0.21 | $0.65 | ||
| Q4 24 | $-0.14 | $0.54 | ||
| Q3 24 | $-0.15 | $0.73 | ||
| Q2 24 | $-0.33 | $0.75 | ||
| Q1 24 | $0.34 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $734.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $3.0B |
| 总资产 | $465.9M | $27.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRWAFD
| Q4 25 | $167.9M | $734.9M | ||
| Q3 25 | $92.4M | $657.3M | ||
| Q2 25 | $86.1M | $809.3M | ||
| Q1 25 | $114.6M | $1.2B | ||
| Q4 24 | $144.8M | $1.5B | ||
| Q3 24 | $144.7M | $2.4B | ||
| Q2 24 | $189.3M | $2.5B | ||
| Q1 24 | $226.6M | $1.5B |
股东权益ESPRWAFD
| Q4 25 | $-302.0M | $3.0B | ||
| Q3 25 | $-451.4M | $3.0B | ||
| Q2 25 | $-433.5M | $3.0B | ||
| Q1 25 | $-426.2M | $3.0B | ||
| Q4 24 | $-388.7M | $3.0B | ||
| Q3 24 | $-370.2M | $3.0B | ||
| Q2 24 | $-344.2M | $3.0B | ||
| Q1 24 | $-294.3M | $2.9B |
总资产ESPRWAFD
| Q4 25 | $465.9M | $27.3B | ||
| Q3 25 | $364.0M | $26.7B | ||
| Q2 25 | $347.1M | $26.7B | ||
| Q1 25 | $324.0M | $27.6B | ||
| Q4 24 | $343.8M | $27.7B | ||
| Q3 24 | $314.1M | $28.1B | ||
| Q2 24 | $352.3M | $28.6B | ||
| Q1 24 | $373.1M | $30.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $60.5M |
| 自由现金流经营现金流 - 资本支出 | — | $50.0M |
| 自由现金流率自由现金流/营收 | — | 26.1% |
| 资本支出强度资本支出/营收 | 0.0% | 5.5% |
| 现金转化率经营现金流/净利润 | — | 0.94× |
| 过去12个月自由现金流最近4个季度 | — | $377.9M |
8季度趋势，按日历期对齐
经营现金流ESPRWAFD
| Q4 25 | $45.2M | $60.5M | ||
| Q3 25 | $-4.3M | $237.0M | ||
| Q2 25 | $-31.4M | $58.0M | ||
| Q1 25 | $-22.6M | $72.1M | ||
| Q4 24 | $-35.0M | $49.4M | ||
| Q3 24 | $-35.3M | $439.2M | ||
| Q2 24 | $-7.2M | $63.1M | ||
| Q1 24 | $53.8M | $169.2M |
自由现金流ESPRWAFD
| Q4 25 | — | $50.0M | ||
| Q3 25 | — | $208.2M | ||
| Q2 25 | — | $53.1M | ||
| Q1 25 | — | $66.6M | ||
| Q4 24 | — | $43.0M | ||
| Q3 24 | $-35.5M | $414.6M | ||
| Q2 24 | $-7.3M | $58.3M | ||
| Q1 24 | $53.8M | $164.8M |
自由现金流率ESPRWAFD
| Q4 25 | — | 26.1% | ||
| Q3 25 | — | 110.6% | ||
| Q2 25 | — | 28.5% | ||
| Q1 25 | — | 37.0% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | -68.7% | 219.7% | ||
| Q2 24 | -9.9% | 30.0% | ||
| Q1 24 | 39.0% | 95.8% |
资本支出强度ESPRWAFD
| Q4 25 | 0.0% | 5.5% | ||
| Q3 25 | 0.0% | 15.2% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.3% | 13.1% | ||
| Q2 24 | 0.1% | 2.5% | ||
| Q1 24 | 0.1% | 2.6% |
现金转化率ESPRWAFD
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 3.91× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.05× | ||
| Q3 24 | — | 7.18× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | 0.88× | 10.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
WAFD
暂无分部数据
